Literature DB >> 29514137

Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.

Mariko Umezawa, Noriyuki Kawami, Shintaro Hoshino, Yoshimasa Hoshikawa, Eriko Koizumi, Nana Takenouchi, Yuriko Hanada, Mitsuru Kaise, Katsuhiko Iwakiri.   

Abstract

BACKGROUND: The study aimed to evaluate the efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis (RE).
METHODS: On-demand therapy by taking one 20-mg tablet of vonoprazan only when reflux symptoms occurred was performed for 24 weeks using 30 patients with mild RE who were receiving maintenance therapy with proton pomp inhibitors (PPIs). The presence or absence of RE, degree of overall satisfaction with the treatment, score of symptoms, and fasting gastrin level before breakfast were examined before and after on-demand therapy. The number of tablets taken during the 24-week period was also noted.
RESULTS: One of the 30 patients dropped out of on-demand therapy 1 week after its initiation. Remission was maintained in 25 (86.2%) of the 29 patients (all 10 [100%] Los Angeles classification grade A patients and 15 (78.9%) of the 19 grade B patients). However, 4 grade B patients exhibited grade B relapse. There were no differences in the degree of overall satisfaction, score of symptoms or the gastrin level between PPI and on-demand therapies. The number of vonoprazan tablets taken during the observation period was 33 tablets (median)/24 weeks.
CONCLUSION: On-demand therapy using 20-mg vonoprazan tablets is an effective alternative maintenance therapy for mild RE.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Maintenance therapy; Mild reflux esophagitis; On-demand therapy; Vonoprazan

Mesh:

Substances:

Year:  2018        PMID: 29514137     DOI: 10.1159/000485795

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

1.  Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.

Authors:  Tomohide Tanabe; Shintaro Hoshino; Noriyuki Kawami; Yoshimasa Hoshikawa; Yuriko Hanada; Nana Takenouchi; Osamu Goto; Mitsuru Kaise; Katsuhiko Iwakiri
Journal:  Esophagus       Date:  2019-05-22       Impact factor: 4.230

2.  Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.

Authors:  Yuta Yokoya; Ataru Igarashi; Akihito Uda; Hisato Deguchi; Toshihisa Takeuchi; Kazuhide Higuchi
Journal:  J Gastroenterol       Date:  2019-08-08       Impact factor: 7.527

Review 3.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

4.  Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.

Authors:  Yasuki Habu
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

5.  Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.

Authors:  Yasuki Habu; Ryuhei Hamasaki; Motonobu Maruo; Tatsuya Nakagawa; Yuki Aono; Daisaku Hachimine
Journal:  J Gen Fam Med       Date:  2021-02-21

Review 6.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.

Authors:  Katsuhiko Iwakiri; Yasuhiro Fujiwara; Noriaki Manabe; Eikichi Ihara; Shiko Kuribayashi; Junichi Akiyama; Takashi Kondo; Hiroshi Yamashita; Norihisa Ishimura; Yuichi Kitasako; Katsunori Iijima; Tomoyuki Koike; Nobuo Omura; Tsutomu Nomura; Osamu Kawamura; Shuichi Ohara; Soji Ozawa; Yoshikazu Kinoshita; Satoshi Mochida; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-02-28       Impact factor: 7.527

7.  Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.

Authors:  Zhenhua Wang; Ruixiaotong Sun; Yanan Sheng; Shuli Qu; Lu Dong; Bin Wu
Journal:  Ann Transl Med       Date:  2022-04

8.  Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.

Authors:  Eunsol Yang; Seokuee Kim; Bongtae Kim; Boram Kim; Yechan Kim; Sung Sup Park; Geun Seog Song; Kyung-Sang Yu; In-Jin Jang; SeungHwan Lee
Journal:  Br J Clin Pharmacol       Date:  2022-02-23       Impact factor: 3.716

Review 9.  Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review.

Authors:  Décio Chinzon; Joaquim Prado P Moraes-Filho; Gerson Domingues; Juliana Leite Soares Guedes; Cláudia Yang Santos; Schlioma Zaterka
Journal:  Prz Gastroenterol       Date:  2021-12-08

10.  Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors.

Authors:  Shohei Sumi; Norihisa Ishimura; Hironobu Mikami; Eiko Okimoto; Yuji Tamagawa; Tsuyoshi Mishiro; Yoshikazu Kinoshita; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2021-07-30       Impact factor: 4.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.